Stock Ratings / Health Care / CI / insiders

ELV (70) NTRA (70) HUM (64) ILMN (77) ⌘ Pro Terminal →

The Cigna Group (CI) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$298.23 -0.06% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $297.63

The Cigna Group (CI) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $78.85B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, The Cigna Group (NYSE: CI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $298.23 (-0.06% 1D, market cap $78.85B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CI ranks #251 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CI compare to ELV and NTRA in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), CI carries a Roarable D+ (53/100 RQD), trailing P/E of 13.2x, gross margin of 21.8%, and ROIC of 8.8%. By comparison, ELV (Elevance Health Inc.) holds a B- grade (70/100 RQD, P/E 16.1x, ROIC 8.7%, cap $91.18B) and NTRA (Natera Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC -4.9%, cap $62.85B). Among the 5-stock peer group, CI leads on earnings multiple (13.2x) while ILMN leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CI?

▼

Per CI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739940), The Cigna Group generated $274.90B in revenue (+11.2% YoY), $5.96B in net income, and -$2.77B in free cash flow against $157.92B in total assets and $52.22B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $297.63 (-0.20%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CI)Realized 20D OHLCV Swing Band: ±5%

Deterministic 5-Pillar Attribution (53/100 Composite)

🔍 WHY CI SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (30% of score)

20D Institutional Volume Accumulation (±5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (23% of score)

Altman Z-Score 2.70 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 3.3% operating margin leave 13 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$282.53+8.5% Next Q

Q2 (-2Q)

Grade D$306.60-2.7% Next Q

Q3 (-1Q)

Grade C-$298.28+0% Next Q

Current

Grade D+$298.23-0.9% Hist 90D α

Trajectory: D (45) → D+ (53)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CI currently carries a cautious 53/100 (D+) rating due to Cash Engine Quality (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($284.69) and Max Pain ($313.14) forces dealer call-delta covering toward $343.99.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.80% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 53%NO 47%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CI Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CI)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CI. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CI)

✓Walkthrough of CI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.76%📐 HORIZONTAL RANGE

2026-11-02O $295.0H $298.4L $295.0C $298.2VOL 1.27M

RES: $317.2SUP: $262.7SMA50: $284.7SMA200: $281.9

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CI Butterfly Map → + Track CI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

4.5%/yr Implied 5Y Growth

vs. +11.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CI)

Health Care Rank #251 of 1016 ⚔️ ELV vs CI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CI vs. ELV, NTRA, HUM, ILMN)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, The Cigna Group (CI) ranks #251 by composite RQD confidence (53/100, grade D+) and #29 by equity capitalization ($78.85B). Within this direct 5-issuer industry benchmark cohort, CI leads on earnings valuation at 13.2x trailing P/E, while ILMN leads on capital efficiency and profitability with 18.2% ROIC and 66.1% gross margin. ILMN currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with CI at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CI ACTIVE The Cigna Group	D+	53/100	13.2x	21.8%	8.8%	-0.06%	$78.85B	Benchmark Subject
ELV Elevance Health Inc.	B-	70/100	16.1x	89.4%	8.7%	-0.46%	$91.18B	/elv-vs-ci →
NTRA Natera Inc.	B-	70/100	—	—	-4.9%	-4.98%	$62.85B	/ntra-vs-ci →
HUM Humana Inc.	C	64/100	42.2x	—	8.3%	-0.73%	$50.14B	/hum-vs-ci →
ILMN Illumina Inc.	B+	77/100	51.5x	66.1%	18.2%	-18.64%	$43.80B	/ilmn-vs-ci →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001739940

In its most recent audited fiscal period (FY2025, filed 2025-12-31), The Cigna Group (CI) reported GAAP revenue of $274.90B (+11.2% vs. FY2024 revenue of $247.12B , and +40.8% cumulative change since FY2023) , GAAP net income of $5.96B, operating cash flow of $9.60B, and free cash flow of -$2.77B (-265.6% YoY). On the balance sheet, CI closed FY2025 with $157.92B in total assets against $52.22B in total debt (Altman Z-Score: 2.70, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$274.90B	$5.96B	$9.60B	-$2.77B	$157.92B	$52.22B
FY2024 (FY)	2024-12-31	$247.12B	$3.43B	$10.36B	-$757.4M	$155.88B	$51.59B
FY2023 (FY)	2023-12-31	$195.26B	$5.16B	$11.81B	$3.03B	$234.32B	$54.83B

3. CI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CI compare to ELV and NTRA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CI?

Where is CI trading relative to its 50-day, 200-day, and 52-week technical levels?

CI last traded at $298.23 (-0.06% on volume of 1,862,175 shares), positioning the stock +4.76% above its 50-day simple moving average ($284.69) and +5.80% above its 200-day simple moving average ($281.88). Across its 52-week range of $239.51 to $316.27, CI sits at the 76.5% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($283.32 to $313.14).

CI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CI insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CI leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: CI RQD Cockpit CI 12M Forecast CI Earnings & Move CI Dividends & DRIP CI Insiders & 13F CI Whale Options CI Profit Sankey CI News & Why

Sector Peer Dials

Labcorp Holdings Inc.

73 /100

CI Core Snapshot

Market Cap $78.85B

Trailing / Fwd P/E 13.2x / 12.3x

Gross Profit Margin 21.8%

Return on Capital (ROIC) 8.8%

Free Cash Flow Yield -3.51%

12M Base Price Target $291.52

FREE TRADER TOOLS

Own CI Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With CI → 🏆 Trade CI in $100K Prop Arena →

CI Wire

Why It Moved →

Direct Company Event Yahoo Finance • 8h ago

What You Need to Know Ahead of The Cigna Group’s Earnings Release

Direct Company Event Trefis • 11h ago

Has Buying Cigna Stock At A High Paid Off?

Direct Company Event GuruFocus • 14h ago

A Look at The Cigna Group (CI) After 3.2% Gain -- GF Value $395.

Direct Company Event Seeking Alpha • 17h ago

The Cigna Group: Client Retention Matters, But Contract Profitability Matters More (CI)

Direct Company Event StockInvest.us • 20h ago

Cigna Stock Price Forecast. Should You Buy CI?

ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CI — The Cigna Group: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:10:21Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CI scores 53 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 7 / 20 (ROIC 8.8%; FCF yield -3.51%); Whale 13F Flow at 16 / 20 (institutional accumulation and options positioning); Insider Conviction at 9 / 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 9 / 20 (Beta 1.12; sector sensitivity); and Forensic Balance Sheet at 12 / 20 (Altman Z 2.7; Piotroski F 5/9; Debt/Equity 1.17).

The weakest pillar is the Fundamental Cash Engine, where a negative free-cash-flow yield offsets a respectable ROIC figure. The strongest pillar is institutional flow, which the rating credits with accumulation and positioning signals. For a prospective investor, the upside case rests on institutional interest and a forward P/E below the trailing P/E, while the valuation tradeoff is that the rating's cash-generation and insider-conviction pillars do not confirm that optimism. The balance-sheet pillar is middling rather than distressed. Per the Roarable RQD rating, the overall reading is a sell-side-style caution: weak fundamentals with a trim orientation.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
298.41	$78.85B	13.2	12.3	6.1	22.54	2.04%	1.12	$239.51 - $316.27	8.8%

Business

Per the SEC financials and market profile, The Cigna Group is a NYSE-listed issuer in the Health Care sector, Medical Specialities industry. The source data reports revenue of $274900.0M for FY 2025 but does not describe its products, customers, or revenue model. Not available in source data for the specific revenue mix and customer segments.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$274900.0M	$9200.0M	$5957.0M	N/A	$-2769.5M	$7676.0M	$52220.2M
FY 2024	$247121.0M	$9417.0M	$3434.0M	N/A	$-757.4M	$7550.0M	$51587.1M
FY 2023	$195265.0M	$8536.0M	$5164.0M	N/A	$3026.1M	N/A	$54830.4M

Per the market data, gross margin is 21.8%, operating margin 3.3%, and net margin 2.2%, with ROIC at 8.8%. Free cash flow was negative in both FY 2025 and FY 2024 after a positive FY 2023. Per the Roarable RQD rating, the Altman Z-Score is 2.7 and the Piotroski F-Score is 5 out of 9, with Debt/Equity at 1.17. Reported debt has risen from $51587.1M to $52220.2M across FY 2024 to FY 2025.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items reference CI. Headlines center on an upcoming earnings release, institutional and valuation commentary, and client retention and contract profitability. Two items are tagged as catalysts with a GREEN light (a GuruFocus piece citing a GF Value of $395 after a 3.2% gain, and a Seeking Alpha piece on client retention versus contract profitability). The remaining items are tagged as market-wire coverage with a YELLOW light. The most time-sensitive watch item is the upcoming earnings release referenced in the first headline. The butterfly supply-chain graph contains no proprietary signals or links.

Open Questions

What are the company's specific revenue segments and how do they contribute to the reported FY 2025 revenue?
What drove the negative free cash flow in FY 2025 and FY 2024, and is the FY 2023 positive figure representative of a trend?
What is the FY 2025 cash balance year-over-year, given FY 2023 cash is listed as N/A?
What are the EPS figures for the reported fiscal years, which are all listed as N/A?
What are the terms and timing of the upcoming earnings release referenced in the news feed?

CI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for The Cigna Group (CI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 8h ago

What You Need to Know Ahead of The Cigna Group’s Earnings Release

Yahoo Finance report covering The Cigna Group (CI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 11h ago

Has Buying Cigna Stock At A High Paid Off?

Trefis report covering The Cigna Group (CI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 14h ago

A Look at The Cigna Group (CI) After 3.2% Gain -- GF Value $395.

GuruFocus report covering The Cigna Group (CI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 17h ago

The Cigna Group: Client Retention Matters, But Contract Profitability Matters More (CI)

Seeking Alpha report covering The Cigna Group (CI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 20h ago

Cigna Stock Price Forecast. Should You Buy CI?

StockInvest.us report covering The Cigna Group (CI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 23h ago

CVS Health (CVS) vs Cigna (CI): Which is a Better Stock to Buy?

Yahoo Finance report covering The Cigna Group (CI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

If You Invested $100 In Cigna Group Stock 20 Years Ago, You Would Have This Much Today

Benzinga report covering The Cigna Group (CI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Cigna (CI) Stock May Still Be Discounted As Health Services Rebound

Simply Wall St report covering The Cigna Group (CI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CI Bull vs. Bear Conversation Board — What's Your Call at $298.23?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CI 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $322.28 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CI (D+ • RQD 53/100) a Buy at $298.41?

Welcome to the CI (The Cigna Group) Roar Pit. Current RQD Composite is 53/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $232.76 (-22.0%)

Spot @ $298.41

Pump the brakes on CI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CI, but look at what you are paying: 13.2x trailing P/E with 21.8% gross margins. Unless The Cigna Group expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $373.01 (+25.0%)

Spot @ $298.41

CI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CI, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $298.41 (52-wk range $239.51 - $316.27), any beat on forward guidance forces shorts and underweight funds to chase.